Pear Therapeutics, Inc. Class A Common Stock
PEAR
PEAR was delisted on the 18th of April, 2023.
18 hedge funds and large institutions have $26.9M invested in Pear Therapeutics, Inc. Class A Common Stock in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
10.13% more ownership
Funds ownership: 0% → 10.13% (+10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.92M |
| 2 |
SCM
Saba Capital Management
New York
|
+$6.42M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$2.41M |
| 4 |
OCM
Oribel Capital Management
New York
|
+$2.05M |
| 5 |
SC
Sculptor Capital
New York
|
+$1.93M |
Top Sellers
PEAR Hedge Fund Activity: Q1 2021 in Review
18 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q1 2021, worth a combined $26.9M.
Buyers outnumbered sellers: 18 funds opened new PEAR positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $6.92M.
- 18 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $26.9M of Pear Therapeutics, Inc. Class A Common Stock stock for Q1 2021.
- 18 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q1 2021 and 0 closed out, a net change of +18 holders.
- The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q1 2021 was Citadel Advisors, an estimated $6.92M added.
Based on aggregated 13F filings for Q1 2021.